RU2007120254A - Новые способы применения агонистов эстрогена бета - Google Patents
Новые способы применения агонистов эстрогена бета Download PDFInfo
- Publication number
- RU2007120254A RU2007120254A RU2007120254/14A RU2007120254A RU2007120254A RU 2007120254 A RU2007120254 A RU 2007120254A RU 2007120254/14 A RU2007120254/14 A RU 2007120254/14A RU 2007120254 A RU2007120254 A RU 2007120254A RU 2007120254 A RU2007120254 A RU 2007120254A
- Authority
- RU
- Russia
- Prior art keywords
- carbon atoms
- alkyl
- halogen
- alkenyl
- carbon
- Prior art date
Links
- 0 CC(C)[C@@]([C@@](C)[C@@](C)C(C1=C(C)C2[C@](*)CCC(C)[C@@](C)[C@@](C)[C@]2CC1)=CC)(C1CC1)*=C Chemical compound CC(C)[C@@]([C@@](C)[C@@](C)C(C1=C(C)C2[C@](*)CCC(C)[C@@](C)[C@@](C)[C@]2CC1)=CC)(C1CC1)*=C 0.000 description 3
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A61K31/055—Phenols the aromatic ring being substituted by halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63714404P | 2004-12-17 | 2004-12-17 | |
| US60/637,144 | 2004-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007120254A true RU2007120254A (ru) | 2009-01-27 |
Family
ID=36143266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007120254/14A RU2007120254A (ru) | 2004-12-17 | 2005-12-15 | Новые способы применения агонистов эстрогена бета |
Country Status (20)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1984028A2 (en) * | 2006-02-14 | 2008-10-29 | Wyeth a Corporation of the State of Delaware | Aqueous pharmaceutical formulations of er selective ligands |
| WO2010105035A2 (en) * | 2009-03-11 | 2010-09-16 | University Of South Florida | Prevention, treatment, and diagnosis of alzheimer's disease through electromagnetic field exposure |
| US10149982B2 (en) | 2009-03-11 | 2018-12-11 | University Of South Florida | Prevention and treatment of brain diseases and disorders related to abnormal protein aggregation through electromagnetic field treatment |
| US10758496B2 (en) * | 2014-09-02 | 2020-09-01 | The Regents Of The University Of California | Estrogen receptor ligand treatment for neurodegenerative diseases |
| WO2018183800A1 (en) * | 2017-03-30 | 2018-10-04 | Marquette University | Substituted (4'-hydroxyphenyl)cycloalkane and (4'-hydroxyphenyl)cycloalkene compounds and uses thereof as selective agonists of the estrogen receptor beta isoform for enhanced memory consolidation |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5990078A (en) * | 1995-07-14 | 1999-11-23 | The Trustees Of Columbia University In The City Of New York | Means of increasing estrogen receptor levels in neural tissue |
| FR2739777B1 (fr) * | 1995-10-11 | 1997-11-14 | Cird Galderma | Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose |
| WO1998021946A1 (en) * | 1996-11-18 | 1998-05-28 | Internutria, Inc. | Composition and treatment for persistent reproductive transition symptoms |
| US20040092010A1 (en) * | 2002-04-15 | 2004-05-13 | Ariel Ruiz I Altaba | Method of proliferating and inducing brain stem cells to differentiate to neurons |
| TR200102992T2 (tr) * | 1999-04-16 | 2004-12-21 | Astrazeneca Ab | ß östrojen reseptörü ligandları. |
| JP2004515496A (ja) * | 2000-12-07 | 2004-05-27 | アストラゼネカ・アクチエボラーグ | ベンズイミダゾール治療剤 |
| WO2002051821A1 (en) * | 2000-12-22 | 2002-07-04 | Astrazeneca Ab | Therapeutic compounds |
| US20030096264A1 (en) * | 2001-06-18 | 2003-05-22 | Psychiatric Genomics, Inc. | Multi-parameter high throughput screening assays (MPHTS) |
| DE60116109T2 (de) * | 2001-11-07 | 2006-09-07 | Schering Ag | In vitro Screening nach Liganden des Östrogenrezeptors |
| UA83620C2 (ru) * | 2001-12-05 | 2008-08-11 | Уайт | Замещенные бензоксазолы и их аналоги как эстрогенные агенты |
| TWI306450B (en) * | 2001-12-13 | 2009-02-21 | Wyeth Corp | Substituted phenyl naphthalenes as estrogenic agents |
| TW200301107A (en) * | 2001-12-13 | 2003-07-01 | Wyeth Corp | Substituted 6H-dibenzo[c,h]chromenes as estrogenic agents |
| US6774248B2 (en) * | 2001-12-18 | 2004-08-10 | Wyeth | Substituted 2-phenyl benzofurans as estrogenic agents |
| WO2004026290A1 (en) * | 2002-09-19 | 2004-04-01 | Merck & Co., Inc. | Method for treating depression and/or anxiety |
| CL2004000985A1 (es) * | 2003-05-16 | 2005-01-14 | Wyeth Corp | Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc |
| US7157492B2 (en) * | 2004-02-26 | 2007-01-02 | Wyeth | Dibenzo chromene derivatives and their use as ERβ selective ligands |
| JP2008505095A (ja) * | 2004-07-01 | 2008-02-21 | ワイス | エストロゲンリガンドとしての四環式化合物 |
-
2005
- 2005-12-15 RU RU2007120254/14A patent/RU2007120254A/ru not_active Application Discontinuation
- 2005-12-15 EP EP05854149A patent/EP1824478A2/en not_active Withdrawn
- 2005-12-15 MX MX2007007347A patent/MX2007007347A/es unknown
- 2005-12-15 US US11/304,037 patent/US20060135574A1/en not_active Abandoned
- 2005-12-15 KR KR1020077013666A patent/KR20070086329A/ko not_active Withdrawn
- 2005-12-15 AR ARP050105297A patent/AR051844A1/es unknown
- 2005-12-15 TW TW094144391A patent/TW200637545A/zh unknown
- 2005-12-15 AU AU2005316561A patent/AU2005316561A1/en not_active Abandoned
- 2005-12-15 CN CNA2005800434508A patent/CN101321524A/zh active Pending
- 2005-12-15 BR BRPI0519111-4A patent/BRPI0519111A2/pt not_active IP Right Cessation
- 2005-12-15 PA PA20058656601A patent/PA8656601A1/es unknown
- 2005-12-15 CA CA002590258A patent/CA2590258A1/en not_active Abandoned
- 2005-12-15 JP JP2007546887A patent/JP2008524236A/ja active Pending
- 2005-12-15 GT GT200500370A patent/GT200500370A/es unknown
- 2005-12-15 WO PCT/US2005/045375 patent/WO2006065968A2/en not_active Ceased
-
2006
- 2006-01-03 PE PE2006000026A patent/PE20061113A1/es not_active Application Discontinuation
-
2007
- 2007-05-24 NO NO20072658A patent/NO20072658L/no not_active Application Discontinuation
- 2007-05-31 IL IL183604A patent/IL183604A0/en unknown
- 2007-06-14 NI NI200700152A patent/NI200700152A/es unknown
- 2007-06-15 ZA ZA200705103A patent/ZA200705103B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0519111A2 (pt) | 2008-12-23 |
| CN101321524A (zh) | 2008-12-10 |
| PA8656601A1 (es) | 2006-12-07 |
| AR051844A1 (es) | 2007-02-14 |
| WO2006065968A8 (en) | 2008-09-12 |
| IL183604A0 (en) | 2007-10-31 |
| AU2005316561A1 (en) | 2006-06-22 |
| MX2007007347A (es) | 2007-07-13 |
| NO20072658L (no) | 2007-09-12 |
| WO2006065968A2 (en) | 2006-06-22 |
| PE20061113A1 (es) | 2006-11-06 |
| CA2590258A1 (en) | 2006-06-22 |
| WO2006065968A3 (en) | 2008-04-10 |
| TW200637545A (en) | 2006-11-01 |
| GT200500370A (es) | 2006-07-13 |
| NI200700152A (es) | 2008-06-17 |
| KR20070086329A (ko) | 2007-08-27 |
| JP2008524236A (ja) | 2008-07-10 |
| EP1824478A2 (en) | 2007-08-29 |
| ZA200705103B (en) | 2009-11-25 |
| US20060135574A1 (en) | 2006-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Haus et al. | Biological clocks and shift work: circadian dysregulation and potential long-term effects | |
| RU2003124653A (ru) | Производные пурина в качестве антагонистов пуринергических рецепторов | |
| JP6352413B2 (ja) | 感覚的不快感の治療向け局所薬としてのジ−イソプロピル−アルカン(dapa)化合物 | |
| JP2001527068A5 (cg-RX-API-DMAC7.html) | ||
| EP2254577A1 (en) | Ampa receptor antagonists for epilepsy, mental disorders or deficits in sensory organ | |
| JP2015514679A5 (cg-RX-API-DMAC7.html) | ||
| RU2011149637A (ru) | Феноксиметильные гетероциклические соединения | |
| WO2009054544A1 (en) | Ampa receptor antagonists for parkinson's disease and movement disorders | |
| Volkan et al. | Known object loss, disturbance in reality testing, and “ee-grief work” as a method of brief psychotherapy | |
| DE69936994T2 (de) | Verfahren zur behandlung von okularen neovaskularen erkrankungen | |
| KR950702551A (ko) | 염증 및 면역 질환의 치료용 2,5-디아릴 테트라히드로티오펜, 2,5-디아릴 테트라히드로푸란 및 그 유사물(2,5-diaryl tetrahydro-thiophene, furans and analogs for the treatment of inflamimatory and immune disorders) | |
| JP2008524236A5 (cg-RX-API-DMAC7.html) | ||
| AU2004204814A1 (en) | Method of treating cognitive decline due to sleep deprivation and stress | |
| Misra et al. | Pharmacotherapy of insomnia and current updates | |
| KR102301073B1 (ko) | 시노카브 또는 이의 약학적으로 허용가능한 염을 포함하는 약학적 조성물 및 이를 이용하여 운동이상증 및 관련 장애를 치료하는 방법 | |
| Schlebusch, L., Pillay, BJ & Louw | Depression and self-report disclosure after live related donor and cadaver renal transplants | |
| TW201440769A (zh) | N-2-羥基-乙基-六氫吡-n’-2-乙磺酸(hepes)之止痛及反轉髓鞘脫失損傷用途 | |
| Levay et al. | Concurrent sex therapy and psychoanalytic psychotherapy by separate therapists: Effectiveness and implications | |
| CN115671188A (zh) | 一种眼睛主动吸收氨基酸技术配方 | |
| Levine | Helping men to control ejaculation | |
| Reddy | Psychological approach to ejaculatory disorders | |
| Bitzer | Definition and diagnosis of sexual problems | |
| Das et al. | Intermittent theta burst stimulation using H7 coil for management of negative symptoms and cognitive dysfunction in chronic schizophrenia: A case report | |
| Jasiński | The psychological difficulties of adapting to the aging process | |
| Barbee et al. | Psychological aspects of vitiligo in negroes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20100419 |